Targeting GD2 after allogeneic SCT: effector cell composition defines the optimal use of ch14.18 and the bispecific antibody construct NG-CU (GD2-CD3)

We investigated whether T cell-recruiting bispecific anti-CD3/GD2 antibody NG-CU might be an alternative to therapeutic anti-GD2 monoclonal antibody (mAb) ch14.18, mediating complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) through natural killer (NK) c...

Descripción completa

Detalles Bibliográficos
Autores principales: Arendt, A.-M., Heubach, F., Maier, C. P., Giardino, S., Jung, G., Kowalewski, E., Rabsteyn, A., Amorelli, G., Seitz, C., Schlegel, P., Handgretinger, R., Lang, P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10576705/
https://www.ncbi.nlm.nih.gov/pubmed/37742286
http://dx.doi.org/10.1007/s00262-023-03536-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10576705/
https://www.ncbi.nlm.nih.gov/pubmed/37742286
http://dx.doi.org/10.1007/s00262-023-03536-x

Ejemplares similares